Clinical Trials Logo

Recurrent Endometrial Cancer clinical trials

View clinical trials related to Recurrent Endometrial Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04906382 Terminated - Lynch Syndrome Clinical Trials

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

NCT ID: NCT03277482 Terminated - Clinical trials for Recurrent Ovarian Carcinoma

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Start date: June 1, 2018
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: - Durvalumab - Tremelimumab